Build a commercialization strategy that actually closes accounts.
RevWorx is the AI-native commercialization operating system for medical device, diagnostics, pharmaceutical, health technology, and medical equipment companies that have cleared or been approved and need a repeatable path from first account to scaled revenue. The homepage shows what the product does. This page shows how the strategy gets built: what goes into the scoring, what the first 90 days look like, how evidence and payer work run in parallel, and how the motion changes by category.
Most teams win the regulatory milestone, then lose time in the commercial gray zone
Without dedicated commercial infrastructure, even strong products struggle to reach the right accounts, clinicians, and payers at the right time.
Spreadsheet-based targeting
Account lists live in CRMs, spreadsheets, and slide decks, so prioritization depends on memory rather than signal.
Unclear buying committees
A capital purchase can involve 8–14 stakeholders per account. Teams often lack visibility into who influences, who decides, and who blocks.
Consumables run on a different motion
For consumables, wound care, and lab-run diagnostics, the gate is clinician preference, formulary or item-master listing, and distributor pull-through — not a committee calendar. Reorder behavior, not one signature, decides the account.
Slow first-contract velocity
12–18 months of commercial buildout compresses runway and delays the evidence needed to raise the next round.
How an account actually earns its rank
The ranked list is the output. These are the inputs behind it, and the reasoning stays visible for every account so your team can argue with the score instead of guessing at it.
Adoption Readiness
Site-of-care characteristics, existing install base or lab platform, procedure or test infrastructure, and whether the account has adopted an adjacent technology in the last 24 months.
Clinical Fit
Case mix, indication volume, and referral patterns matched against the specific label and evidence you actually hold — not a broad specialty filter.
Procedure or Volume Momentum
Direction of travel, not just size. A mid-sized account growing 18% quarter over quarter usually converts faster than a flat flagship.
Economic and Coverage Position
Regional payer posture, coverage status for the indication, and the account's exposure to the cost line your product moves.
Timing Triggers
Incumbent contract renewals, new service-line leadership, competitor clearances, published coverage changes — the reason this account is workable now rather than someday.
Confidence Labeling
Every input is marked REAL or MODELED. A high score built on modeled inputs is treated as a hypothesis to test, not a fact to act on.
Scores are recomputed as signals change, so an account that was ranked 40th in January can surface at the top in March when its contract clock starts running — with the specific trigger named, not implied.
The first 90 days, concretely
Not a discovery phase followed by a deck. Each 30-day block ends with something your team can act on and leadership can review.
Baseline and target definition
- Goal statement: offering, indication, geography, and the contract count that defines success
- Audit of what already exists — evidence, references, pricing logic, prior conversations
- First ranked account and clinician list, with reasoning reviewed line by line with your team
- Named gaps: the claims you cannot yet support and the data you need to support them
Engagement and evidence pressure-testing
- Recommended play per account, with meeting briefs and evidence summaries drafted
- Stakeholder map per target: champion, economic buyer, blocker, and the path between them
- Objection log built from real calls, fed back into positioning and collateral
- Early pricing and value-story calibration against what accounts actually push back on
Conversion and repeatability
- Accounts advanced through Target → Engaged → Evaluation → Trial → Signed with an audit trail
- Stalled accounts surfaced automatically with the specific reason they stalled
- What worked codified into a repeatable play a new rep can run without you
- Board-ready view of pipeline, velocity, and the evidence gap that remains
The workstream that decides whether a strong pipeline converts
Targeting gets you the meeting. Evidence and coverage decide whether the meeting turns into a contract.
Coverage before conversation
Whether the indication gets paid for in a given region is established before a rep invests a quarter in the account, not discovered during contracting.
Evidence mapped to objection
Each recurring objection is tied to the specific study, registry, or economic model that answers it — and where nothing answers it, that gap is named rather than talked around.
Economic story per site of care
The same product carries a different value argument in an IDN, an ASC, an independent lab, and a physician office. Each gets its own framing rather than one deck stretched across all four.
Access work runs in parallel
Market access is not a phase after sales. Coverage posture, coding path, and pricing corridors are surfaced at the account level alongside targeting from day one.
The same engine, four different commercial motions
A strategy that treats every product like a capital purchase fails for three quarters of the market. The scoring inputs stay constant; what changes is the gate you are trying to clear.
Committee navigation and capital cycles
Long cycles, value analysis committees, and a capital calendar that determines when a yes is even possible. The work is stakeholder mapping, economic justification, and timing the ask to the budget window.
Clinician pull and distributor economics
The decision sits with the clinician and the supply chain, not a committee. The work is item-master and contract-vehicle listing, distributor incentive alignment, reorder behavior, and conversion inside accounts you already touch.
Ordering behavior and reimbursement path
Adoption depends on who orders the test, whether it fits the existing lab or EHR workflow, and whether the coding and coverage path is settled. The work is ordering-clinician targeting plus a reimbursement narrative that survives a payer conversation.
Formulary, protocol, and integration gates
The gate is a formulary decision, a care-protocol change, or an IT and integration review. The work is mapping that specific gate per account and sequencing evidence to clear it.
Build your commercialization strategy with RevWorx
Schedule a short walkthrough. We'll show you what a ranked target list and a recommended play look like for your product and territory.